Grover Paul Miller
Professor
Also affiliated: Chonnam National University (2010–2018); Pennsylvania State University (1993–2001); University of Helsinki (2009); Vanderbilt University (2000–2002); Washington University in St. Louis (2009–2020); University of Arkansas Medical Center (2016); Arkansas Department of Health (2009–2010); Vanderbilt University Medical Center (2001)
Biochemistry & Molecular Biology, College of Medicine
Research Areas
Biomedical Subjects
Biography and Research Information
OverviewAI-generated summary
Grover Paul Miller's research focuses on understanding the biological significance of metabolic activation and clearance of molecules, particularly in relation to pharmacological and toxicological effects. His group employs analytical and biochemical methods to identify and quantify small molecules, including drugs, pollutants, and food additives, during metabolism. These findings are then correlated with biological activity and in vivo outcomes, such as liver toxicity. Current projects aim to elucidate metabolic mechanisms, efficiencies, and fluxes for the activation and elimination of toxic molecules. Additionally, his work involves identifying metabolite biomarkers in humans and animal models to link in vitro findings with in vivo outcomes, exploring their diagnostic, theranostic, and prognostic potential. Miller also develops computational models for drug bioactivation and clearance to contribute to the reduction of adverse drug events and enhance drug safety for clinical use.
Miller's research has expanded from detailed in vitro metabolic studies to metabolite profiling for translational studies and the development of metabolism models. He seeks to translate novel analytical and diagnostic tools into practical, commercially viable applications. His scholarship metrics include an h-index of 30, 110 total publications, and 2,818 total citations. He has served as PI on two federal grants totaling $84,000 from the NIH/National Institute of Environmental Health Sciences and the NIH/National Institute on Drug Abuse, focusing on toxicological mechanisms and novel metabolic pathways for halogenated drugs of abuse, respectively.
Research Overview
My goals are to assess the biological significance of metabolic activation and clearance of molecules especially related to pharmacological and toxicological effects. In practice, my group leverages powerful analytical and biochemical tools to identify and quantitate small molecules including drugs, pollutants, and food additives during metabolism and correlate findings to biological activity and in vivo outcomes such as liver toxicity. Individual projects aim to (1) determine metabolic mechanisms, efficiencies, and fluxes for activation and elimination of toxic molecules, (2) identify metabolite biomarkers in humans and animal models for correlating in vitro findings to in vivo outcomes and leveraging their diagnostic, theragnostic, and prognostic potential, and (3) develop computational models for drug bioactivation and clearance contributing to adverse drug events to make drugs safer for clinical use. Moreover, I seek translation of novel analytical and diagnostic tools into practical, commercially viable tools. Over time, my research expanded from detailed in vitro metabolic studies to metabolite profiling for translational studies and development of models of metabolism, structure, and reactivity that were made possible through strong, interdisciplinary collaborations.
Metrics
- h-index: 30
- Publications: 104
- Citations: 2,781
Positions
-
Editor in Chief 2025–presentTaylor and Francis (United Kingdom) Drug Metabolism Reviews ORCID
-
Professor 2017–presentUniversity of Arkansas for Medical Sciences Biochemistry & Molecular Biology, College of Medicine Institutional directory
-
Associate Professor 2007–2017University of Arkansas for Medical Sciences Biochemistry and Molecular Biology ORCID
-
Assistant Professor 2001–2007University of Arkansas for Medical Sciences Biochemistry and Molecular Biology ORCID
-
Postdoctoral Fellow 1997–2001Vanderbilt University Biochemistry ORCID
Selected Publications
-
Assessing Pain Linked to High Metabolic and Glycolytic Shift in Neurofibromatosis Type 1 (NF1) Patients by Using a Bioenergetic Biomarker: A Pilot Study (2026)
-
The resurgence of synthetic cannabinoid receptor agonists as adulterants in the Era of Cannabis legalization: Lessons from prior epidemics and clinical implications (2025)
-
Bioactivation and reactivity research advances – 2023 year in review (2024)
-
Biotransformation research advances – 2022 year in review (2023)
-
Bioactivation and reactivity research advances – 2022 year in review‡ (2023)
-
The Role of Cytochrome P450 3A4-Mediated Metabolism in Sorafenib and Lapatinib Hepatotoxicity (2023)
-
Editorial: Advancements in computational studies of drug toxicity (2023)
-
Similar 5F-APINACA Metabolism between CD-1 Mouse and Human Liver Microsomes Involves Different P450 Cytochromes (2022)
-
Bioactivation and reactivity research advances – 2021 year in review (2022)
-
Discovery of Novel Reductive Elimination Pathway for 10-Hydroxywarfarin (2022)
-
CYP2C9 and 3A4 play opposing roles in bioactivation and detoxification of diphenylamine NSAIDs (2021)
-
Machine learning liver-injuring drug interactions with non-steroidal anti-inflammatory drugs (NSAIDs) from a retrospective electronic health record (EHR) cohort (2021)
-
4-Methyl-1,2,3-Triazoles as N -Acetyl-Lysine Mimics Afford Potent BET Bromodomain Inhibitors with Improved Selectivity (2021)
-
Bioactivation of Isoxazole-Containing Bromodomain and Extra-Terminal Domain (BET) Inhibitors (2021)
-
Novel Bioactivation of Isoxazole‐containing Bromodomain and Extra Terminal Domain (BET) Inhibitors (2021)
Federal Grants 2 $84,000 total
Advances in toxicological mechanisms through interdisciplinary research
Research Interests
drug; metabolism; bioactivation; toxicity; in vitro; P450; modeling; Structure Activity Relationship, Quantitative; kinetics
Grants & Funding
As listed on this researcher's institutional profile. Federal awards with verified records are shown above.
- RATE LIMITING STEPS IN CYTOCHROME P450 CATALYSIS NIH Principal Investigator
- Structure-Function of UDP-Glucuronosyltransferases NIH Co-Investigator
- Investigating the Role of Protein-protein Interactions in the Oxidation of Fatty Acids by Cytochrome P4504A11 American Heart Association (Midwest Affiliate) Principal Investigator
- Improving pediatric anticoagulant therapy through metabolic profiling of patients American Heart Association (SouthWest Affiliate) Principal Investigator
- NIH COBRE Center for Protein Structure and Function NIH/Nat. Center for Research Resources Principal Investigator
- Effects of Genetic Diversity on Carcinogen Metabolism NIH Co-Investigator
- Miller ABI Contract UAMS College of Medicine Principal Investigator
- Toxicological Significance of Alkylbenzene Metabolism NIH/Nat. Inst. of Environmental Health Sciences via Louisiana State University Health Sciences Center Principal Investigator
- DATA AND TOOLS FOR MODELING METABOLISM AND REACTIVITY NIH Co-Principal Investigator
- Computationally modeling the impact of ontogeny on drug metabolic fate NIH Principal Investigator
- Systematic Discovery of Bioactivation-Associated Structural Alerts NIH/Nat. Inst. of General Medical Sciences via Washington University Principal Investigator
- Systematic Discovery of Bioactivation-Associated Structural Alerts NIH Co-Principal Investigator
Collaboration Network
Top Collaborators
- Metabolism of R- and S-Warfarin by CYP2C19 into Four Hydroxywarfarins
- Novel multi-mode ultra performance liquid chromatography–tandem mass spectrometry assay for profiling enantiomeric hydroxywarfarins and warfarin in human plasma
- 1,3-Butadiene-induced mitochondrial dysfunction is correlated with mitochondrial CYP2E1 activity in Collaborative Cross mice
- CYP2E1 Metabolism of Styrene Involves Allostery
- Lamisil (terbinafine) toxicity: Determining pathways to bioactivation through computational and experimental approaches
Showing 5 of 21 shared publications
- Modeling Epoxidation of Drug-like Molecules with a Deep Machine Learning Network
- Modeling Reactivity to Biological Macromolecules with a Deep Multitask Network
- Site of Reactivity Models Predict Molecular Reactivity of Diverse Chemicals with Glutathione
- Computationally Assessing the Bioactivation of Drugs by N-Dealkylation
- Machine learning liver-injuring drug interactions with non-steroidal anti-inflammatory drugs (NSAIDs) from a retrospective electronic health record (EHR) cohort
Showing 5 of 21 shared publications
- Metabolism of R- and S-Warfarin by CYP2C19 into Four Hydroxywarfarins
- Kynurenine Signaling Increases DNA Polymerase Kappa Expression and Promotes Genomic Instability in Glioblastoma Cells
- Toxicological implications of mitochondrial localization of CYP2E1
- 1,3-Butadiene-induced mitochondrial dysfunction is correlated with mitochondrial CYP2E1 activity in Collaborative Cross mice
- CYP2E1 hydroxylation of aniline involves negative cooperativity
Showing 5 of 18 shared publications
- 4-Methyl-1,2,3-Triazoles as N -Acetyl-Lysine Mimics Afford Potent BET Bromodomain Inhibitors with Improved Selectivity
- Meloxicam methyl group determines enzyme specificity for thiazole bioactivation compared to sudoxicam
- Dual mechanisms suppress meloxicam bioactivation relative to sudoxicam
- The Role of Cytochrome P450 3A4-Mediated Metabolism in Sorafenib and Lapatinib Hepatotoxicity
- Significance of Multiple Bioactivation Pathways for Meclofenamate as Revealed through Modeling and Reaction Kinetics
Showing 5 of 12 shared publications
- Characterization of Human Hepatic and Extrahepatic UDP-Glucuronosyltransferase Enzymes Involved in the Metabolism of Classic Cannabinoids
- Assessing Cytochrome P450 and UDP-Glucuronosyltransferase Contributions to Warfarin Metabolism in Humans
- Glucuronidation of Monohydroxylated Warfarin Metabolites by Human Liver Microsomes and Human Recombinant UDP-Glucuronosyltransferases
- CYP2E1 active site residues in substrate recognition sequence 5 identified by photoaffinity labeling and homology modeling
- The First Aspartic Acid of the DQxD Motif for Human UDP-Glucuronosyltransferase 1A10 Interacts with UDP-Glucuronic Acid during Catalysis
Showing 5 of 10 shared publications
- Machine learning liver-injuring drug interactions with non-steroidal anti-inflammatory drugs (NSAIDs) from a retrospective electronic health record (EHR) cohort
- Meloxicam methyl group determines enzyme specificity for thiazole bioactivation compared to sudoxicam
- Dual mechanisms suppress meloxicam bioactivation relative to sudoxicam
- CYP2C19 and 3A4 Dominate Metabolic Clearance and Bioactivation of Terbinafine Based on Computational and Experimental Approaches
- Comprehensive kinetic and modeling analyses revealed CYP2C9 and 3A4 determine terbinafine metabolic clearance and bioactivation
Showing 5 of 10 shared publications
- Machine learning liver-injuring drug interactions with non-steroidal anti-inflammatory drugs (NSAIDs) from a retrospective electronic health record (EHR) cohort
- Meloxicam methyl group determines enzyme specificity for thiazole bioactivation compared to sudoxicam
- Stereospecific Metabolism of R- and S-Warfarin by Human Hepatic Cytosolic Reductases
- Dual mechanisms suppress meloxicam bioactivation relative to sudoxicam
- Lamisil (terbinafine) toxicity: Determining pathways to bioactivation through computational and experimental approaches
Showing 5 of 9 shared publications
- Biotransformation and bioactivation reactions – 2016 literature highlights
- Biotransformation and bioactivation reactions – 2017 literature highlights
- Biotransformation and bioactivation reactions – 2018 literature highlights
- Novel advances in biotransformation and bioactivation research – 2020 year in review
- Novel advances in biotransformation and bioactivation research—2019 year in review
Showing 5 of 9 shared publications
- Metabolism of R- and S-Warfarin by CYP2C19 into Four Hydroxywarfarins
- Assessing Cytochrome P450 and UDP-Glucuronosyltransferase Contributions to Warfarin Metabolism in Humans
- Novel multi-mode ultra performance liquid chromatography–tandem mass spectrometry assay for profiling enantiomeric hydroxywarfarins and warfarin in human plasma
- Hydroxywarfarin Metabolites Potently Inhibit CYP2C9 Metabolism ofS-Warfarin
- Warfarin and UDP-glucuronosyltransferases: writing a new chapter of metabolism
Showing 5 of 8 shared publications
- Modeling Epoxidation of Drug-like Molecules with a Deep Machine Learning Network
- Modeling Reactivity to Biological Macromolecules with a Deep Multitask Network
- Site of Reactivity Models Predict Molecular Reactivity of Diverse Chemicals with Glutathione
- Computationally Assessing the Bioactivation of Drugs by N-Dealkylation
- Computational Approach to Structural Alerts: Furans, Phenols, Nitroaromatics, and Thiophenes
Showing 5 of 8 shared publications
- Kynurenine Signaling Increases DNA Polymerase Kappa Expression and Promotes Genomic Instability in Glioblastoma Cells
- Stereospecific Metabolism of R- and S-Warfarin by Human Hepatic Cytosolic Reductases
- Multiple UDP-glucuronosyltransferases in human liver microsomes glucuronidate both R- and S-7-hydroxywarfarin into two metabolites
- Novel isomeric metabolite profiles correlate with warfarin metabolism phenotype during maintenance dosing in a pilot study of 29 patients
- Significance of Competing Metabolic Pathways for 5F-APINACA Based on Quantitative Kinetics
Showing 5 of 7 shared publications
- Characterization of Human Hepatic and Extrahepatic UDP-Glucuronosyltransferase Enzymes Involved in the Metabolism of Classic Cannabinoids
- Glucuronidation of Monohydroxylated Warfarin Metabolites by Human Liver Microsomes and Human Recombinant UDP-Glucuronosyltransferases
- The First Aspartic Acid of the DQxD Motif for Human UDP-Glucuronosyltransferase 1A10 Interacts with UDP-Glucuronic Acid during Catalysis
- Identification of Hydroxywarfarin Binding Site in Human UDP Glucuronosyltransferase 1A10: Phenylalanine90 Is Crucial for the Glucuronidation of 6- and 7-Hydroxywarfarin but Not 8-Hydroxywarfarin
- The glucuronidation of native and oxidized estrogens can be effectively inhibited by compounds structurally related to UDP‐glucuronic acid in human recombinant UGT1A10
Showing 5 of 7 shared publications
- Characterization of Human Hepatic and Extrahepatic UDP-Glucuronosyltransferase Enzymes Involved in the Metabolism of Classic Cannabinoids
- Assessing Cytochrome P450 and UDP-Glucuronosyltransferase Contributions to Warfarin Metabolism in Humans
- Identification of Hydroxywarfarin Binding Site in Human UDP Glucuronosyltransferase 1A10: Phenylalanine90 Is Crucial for the Glucuronidation of 6- and 7-Hydroxywarfarin but Not 8-Hydroxywarfarin
- The glucuronidation of native and oxidized estrogens can be effectively inhibited by compounds structurally related to UDP‐glucuronic acid in human recombinant UGT1A10
- Characterization of mutation in the 395 DQxD 398 motif of the glucuronic acid binding site in human UGT1A6: Comparison to UGT1A10
Showing 5 of 6 shared publications
- Characterization of Human Hepatic and Extrahepatic UDP-Glucuronosyltransferase Enzymes Involved in the Metabolism of Classic Cannabinoids
- Assessing Cytochrome P450 and UDP-Glucuronosyltransferase Contributions to Warfarin Metabolism in Humans
- Glucuronidation of Monohydroxylated Warfarin Metabolites by Human Liver Microsomes and Human Recombinant UDP-Glucuronosyltransferases
- Hydroxywarfarin Metabolites Potently Inhibit CYP2C9 Metabolism ofS-Warfarin
- Warfarin and UDP-glucuronosyltransferases: writing a new chapter of metabolism
Showing 5 of 6 shared publications
- Characterization of Human Hepatic and Extrahepatic UDP-Glucuronosyltransferase Enzymes Involved in the Metabolism of Classic Cannabinoids
- Glucuronidation of Monohydroxylated Warfarin Metabolites by Human Liver Microsomes and Human Recombinant UDP-Glucuronosyltransferases
- The First Aspartic Acid of the DQxD Motif for Human UDP-Glucuronosyltransferase 1A10 Interacts with UDP-Glucuronic Acid during Catalysis
- Identification of Hydroxywarfarin Binding Site in Human UDP Glucuronosyltransferase 1A10: Phenylalanine90 Is Crucial for the Glucuronidation of 6- and 7-Hydroxywarfarin but Not 8-Hydroxywarfarin
- The glucuronidation of native and oxidized estrogens can be effectively inhibited by compounds structurally related to UDP‐glucuronic acid in human recombinant UGT1A10
Showing 5 of 6 shared publications
Similar Researchers
Based on overlapping research topics